This week at #ASGCT2024 Creyon Bio’s CMO, David Dimmock, MD, will present clinical data showing how we used our AI- and data-driven platform to rapidly engineer an antisense oligonucleotide investigational therapy for treatment of an ultra-rare disease. This underscores the potential of AI to create new safe and active oligonucleotide therapeutic candidates with significantly improved efficiency for common and rare diseases targeting the genetic underpinning of disease. https://lnkd.in/dezfE_V9 American Society of Gene & Cell Therapy TNPO2 Foundation
